Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Smith & Nephew PLC

Healthcare GB SN

1108.5GBX
0.00(0%)

Last update at 2026-06-04T07:48:00Z

Day Range

1108.501123.50
LowHigh

52 Week Range

938.591408.18
LowHigh

Fundamentals

  • Previous Close 1108.50
  • Market Cap10511.74M
  • Volume118418
  • P/E Ratio23.24
  • Dividend Yield3.19%
  • EBITDA1336.00M
  • Revenue TTM6164.00M
  • Revenue Per Share TTM7.11
  • Gross Profit TTM 4207.00M
  • Diluted EPS TTM0.53

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 795.34M 498.00M 290.00M 235.00M 586.00M
Minority interest - - - - -
Net income 638.11M 412.00M 263.00M 223.00M 524.00M
Selling general administrative 2790.00M 376.00M 384.00M 2880.00M 2720.00M
Selling and marketing expenses - 2276.00M 2218.00M 2066.00M 2013.00M
Gross profit 4279.95M 4046.00M 3819.00M 3675.00M 3669.00M
Reconciled depreciation 574.00M 555.00M 527.00M 628.00M 581.00M
Ebit 1024.04M 657.00M 429.00M 315.00M 593.00M
Ebitda 1609.06M 1237.00M 956.00M 943.00M 1172.00M
Depreciation and amortization 585.02M 580.00M 527.00M 628.00M 579.00M
Non operating income net other - - - - -
Operating income 1024.04M 657.00M 425.00M 315.00M 593.00M
Other operating expenses 5269.28M 5153.00M 5124.00M 4765.00M 4619.00M
Interest expense 159.27M 168.00M 139.00M 80.00M 80.00M
Tax provision 154.00M 86.00M 27.00M 12.00M 62.00M
Interest income 28.00M 24.00M 34.00M 14.00M 6.00M
Net interest income -128.00000M -149.00000M -105.00000M -74.00000M -91.00000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 157.23M 86.00M 27.00M 12.00M 62.00M
Total revenue 6293.32M 5810.00M 5549.00M 5215.00M 5212.00M
Total operating expenses 3255.91M 3389.00M 3394.00M 3225.00M 3076.00M
Cost of revenue 2013.37M 1764.00M 1730.00M 1540.00M 1543.00M
Total other income expense net -228.69959M -159.00000M -135.00000M -80.00000M -7.00000M
Discontinued operations - - - - -
Net income from continuing ops 625.00M 412.00M 263.00M 223.00M 524.00M
Net income applicable to common shares - - - 223.00M 524.00M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 10460.81M 10354.00M 9987.00M 9966.00M 10920.00M
Intangible assets 882.32M 1032.00M 1110.00M 1236.00M 1398.00M
Earning assets - - - - -
Other current assets - 208.00M 274.00M 1301.00M 1290.00M
Total liab 5169.88M 5089.00M 4770.00M 4707.00M 5352.00M
Total stockholder equity 5290.93M 5265.00M 5217.00M 5259.00M 5568.00M
Deferred long term liab - - - - -
Other current liab 268.10M 154.00M 272.00M 457.00M 544.00M
Common stock 175.06M 175.00M 175.00M 175.00M 177.00M
Capital stock 175.00M 175.00M 175.00M 175.00M 177.00M
Retained earnings 5324.94M 5018.00M 4906.00M 5026.00M 5225.00M
Other liab - - - 280.00M 373.00M
Good will 3109.13M 3026.00M 2992.00M 3031.00M 2989.00M
Other assets - - - 330.00M 398.00M
Cash 557.20M 619.00M 302.00M 350.00M 1290.00M
Cash and equivalents - - - - -
Total current liabilities 1595.58M 1531.00M 2271.00M 1715.00M 2131.00M
Current deferred revenue - - - - -
Net debt 2771.01M 2702.00M 2782.00M 2522.00M 2049.00M
Short term debt 150.05M 63.00M 765.00M 160.00M 491.00M
Short long term debt 83.00M 2.00M 710.00M 111.00M 435.00M
Short long term debt total 3328.21M 3321.00M 3084.00M 2872.00M 3339.00M
Other stockholder equity -229.08342M 72.00M -269.00000M 58.00M 166.00M
Property plant equipment - - - 1455.00M 1513.00M
Total current assets 4104.49M 4421.00M 4030.00M 3856.00M 4424.00M
Long term investments - - - - -
Net tangible assets - - - 992.00M 1181.00M
Short term investments - - -69.00000M - -182.00000M
Net receivables 1429.52M 1207.00M 1059.00M 1264.00M 1290.00M
Long term debt 3028.00M 3123.00M 2175.00M 2565.00M 2707.00M
Inventory 2117.77M 2387.00M 2395.00M 2205.00M 1844.00M
Accounts payable 1177.43M 1082.00M 1016.00M 1098.00M 1096.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 20.01M - -385.00000M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 228.08M 103.00M 361.00M 211.00M 15.00M
Deferred long term asset charges - - - - -
Non current assets total 6356.31M 5933.00M 5957.00M 6110.00M 6496.00M
Capital lease obligations 216.00M 196.00M 199.00M 196.00M 197.00M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -2.00000M -569.00000M -448.00000M -472.00000M 2.00M
Change to liabilities - - - -25.00000M 82.00M
Total cashflows from investing activities -414.51800M -569.00000M -448.00000M -472.00000M -691.00000M
Net borrowings -86.00000M 295.00M 175.00M -450.00000M -326.00000M
Total cash from financing activities -975.03619M -86.00000M -200.00000M -926.00000M -645.00000M
Change to operating activities - - - - -150.00000M
Net income 638.11M 412.00M 290.00M 235.00M 586.00M
Change in cash -107.83163M 317.00M -44.00000M -941.00000M -466.00000M
Begin period cash flow 665.03M 300.00M 344.00M 1285.00M 1751.00M
End period cash flow 557.20M 617.00M 300.00M 344.00M 1285.00M
Total cash from operating activities 1311.96M 987.00M 608.00M 468.00M 877.00M
Issuance of capital stock 12.00M 1.00M 0.00000M 6.00M 14.00M
Depreciation 585.02M 580.00M 527.00M 628.00M 581.00M
Other cashflows from investing activities - -2.00000M - - -
Dividends paid 336.92M 327.00M 327.00M 327.00M 329.00M
Change to inventory 212.36M -42.00000M -178.00000M -407.00000M -151.00000M
Change to account receivables -178.67155M -81.00000M -49.00000M -103.00000M -81.00000M
Sale purchase of stock -512.53211M 0.00000M 0.00000M -158.00000M -59.00000M
Other cashflows from financing activities -50.02804M -55.00000M -48.00000M 434.00M -4.00000M
Change to netincome - - - 232.00M -78.00000M
Capital expenditures 442.08M 381.00M 427.00M 358.00M 408.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 129.66M -123.00000M -332.00000M -535.00000M -150.00000M
Stock based compensation 43.00M 40.00M 39.00M 40.00M 41.00M
Other non cash items -40.83921M 78.00M 84.00M 100.00M 74.00M
Free cash flow 869.88M 606.00M 181.00M 110.00M 469.00M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SN
Smith & Nephew PLC		 - -% 1108.50 23.24 12.47 1.70 2.59 2.67 10.76
NIOX
NIOX Group PLC		 -0.1481 0.24% 60.85 28.20 18.73 4.84 3.41 4.35 13.85
EKF
EKF Diagnostics Holdings Plc		 1.00 3.78% 27.40 - 34.97 2.02 1.46 1.72 7.01
CREO
Creo Medical Group PLC		 -0.2 1.45% 13.55 - - 199.36 0.74 6.21 8.16
AOTI
AOTI Inc		 -3.0 5.08% 56.00 18.25 8.10 0.64 2.76 0.94 8.31

Reports Covered

Stock Research & News

View All

Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Smith & Nephew PLC

Building 5, Watford, United Kingdom, WD18 8YE

Key Executives

Name Title Year Born
Ms. Anne-Francoise Nesmes CFO & Exec. Director 1972
Dr. Deepak S. Nath Ph.D. CEO & Director 1973
Mr. Paul Connolly Pres of Global Operations 1968
Mr. Andrew Swift VP of Investor Relations NA
Ms. Helen Barraclough Group Gen. Counsel, Company Sec. & Director 1979
Ms. Alison Parkes Chief Compliance Officer 1972
Mr. Joe Metzger Sr. VP of Marketing Services & Communications NA
Ms. Elga Lohler Chief HR Officer 1968
Mr. Philip G. Cowdy Chief Bus. Devel. & Corp. Affairs Officer 1967
Mr. Bradley Cannon Pres of Orthopaedics, Sports Medicine & ENT and Americas 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.